ХЭНВУД Джеральдин Энн (US),МЭК Рэндалл Джером (US),ШЭРР Кристофер Томас (US),КОУЛЕНГ Мл. Джон Джозеф (US)
申请号：
RU2011151059/02
公开号：
RU2011151059A
申请日:
2010.05.17
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. A method of treating or preventing pain without significant sedation, comprising sublingually administering to the mammal a pharmaceutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable liquid carrier suitable for sublingual administration, wherein said dexmedetomidine or its pharmaceutically acceptable salt is absorbed sublingually and treats or prevents pain without significant sedation. 2. The method according to claim 1, wherein said pharmaceutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof is from about 0.05 μg / kg to about 1.50 μg / kg. The method of claim 1, wherein said mammal is an adult, and said pharmaceutically effective amount of dexmedetomidine or a pharmaceutically acceptable salt thereof is from about 5 μg to about 50 μg. The method according to claim 1, where Cdexmedetomidine in plasma after sublingual absorption is less than about 0.30 ng / ml. The method according to claim 1, where within an hour immediately after application of the indicated pharmaceutically effective amount, the average blood pressure of a mammal varies by no more than about 20 mm Hg. The method according to claim 1, wherein within an hour immediately after administration of the indicated pharmaceutically effective amount, said animal without significant sedative effect belongs to a category that is at the level of sedative action, which is not more than level 2 on the Ramsay sedative effect scale. The method of claim 1, further comprising administering one or more other analgesics. How1. Способ лечения или предотвращения боли без значительного седативного действия, включающий сублингвальное введение млекопитающему фармацевтически эффективного количества дексмедетомидина или его фармацевтически приемлемой соли в фармацевтически приемлемом жидком носителе, подходящем для сублингвального введения, где указанный дексмедетомидин или его фармацевтически приемлемая соль в
